Loading...
•
Dec 31, 2021
Supernus Q4 2021 Earnings Report
Supernus reported audited financial results, with a change in acquisition-related costs affecting operating earnings.
Key Takeaways
Supernus Pharmaceuticals reported total revenues of $159.1 million and net earnings of $2.4 million for Q4 2021. Operating earnings were $6.1 million. The company reiterated its full-year 2022 financial guidance.
Total revenues for Q4 2021 were $159.1 million.
Operating earnings for Q4 2021 were $6.1 million.
Net earnings for Q4 2021 were $2.4 million.
Combined R&D and SG&A expenses increased by approximately $15.6 million due to non-recurring acquisition-related costs.
Forward Guidance
The Company reiterates the full year 2022 financial guidance as set forth below: Amount ($ in millions)Total revenues (1)$640 - $680 Combined R&D and SG&A expenses$460 - $490 Operating earnings (2)$20 - $40 Effective tax rate25% - 28% Total revenues (1) $640 - $680 Operating earnings (2)
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...